Clinical Characteristics of EGPA Patients in Comparison to GPA Subgroup with Increased Blood Eosinophilia from POLVAS Registry
Anna Drynda,Agnieszka Padjas,Krzysztof Wójcik,Radosław Dziedzic,Grzegorz Biedroń,Katarzyna Wawrzycka-Adamczyk,Anna Włudarczyk,Joanna Wilańska,Jacek Musiał,Zbigniew Zdrojewski,Zenobia Czuszyńska,Anna Masiak,Maria Majdan,Radosław Jeleniewicz,Hanna Augustyniak-Bartosik,Katarzyna Jakuszko,Magdalena Krajewska,Alicja Dębska-Ślizień,Hanna Storoniak,Barbara Bułło-Piontecka,Witold Tłustochowicz,Joanna Kur-Zalewska,Małgorzata Wisłowska,Piotr Głuszko,Marta Madej,Ewa Jassem,Iwona Damps-Konstańska,Eugeniusz Kucharz,Marek Brzosko,Marcin Milchert,Anna Hawrot-Kawecka,Joanna Miłkowska-Dymanowska,Paweł Górski,Anna Lewandowska-Polak,Joanna Makowska,Joanna Zalewska,Lech Zaręba,Stanisława Bazan-Socha
DOI: https://doi.org/10.1155/2024/4283928
IF: 4.4929
2024-04-26
Journal of Immunology Research
Abstract:Objective. To characterize the eosinophilic granulomatosis with polyangiitis (EGPA) population from the POLVAS registry depending on ANCA status and diagnosis onset, including their comparison with the granulomatosis with polyangiitis (GPA) subset with elevated blood eosinophilia (min. 400/μl) (GPA HE) to develop a differentiating strategy. Methods. A retrospective analysis of the POLVAS registry. Results. The EGPA group comprised 111 patients. The ANCA-positive subset (n = 45 [40.54%]) did not differ from the ANCA-negative one in clinics. Nevertheless, cardiovascular manifestations were more common in ANCA-negative patients than in those with anti-myeloperoxidase (MPO) antibodies (46.97% vs. 26.92%, p = 0.045). Patients diagnosed before 2012 (n = 70 [63.06%]) were younger (median 41 vs. 49 years, p <0.01 ), had higher blood eosinophilia at diagnosis (median 4,946 vs. 3,200/μl, p <0.01 ), and more often ear/nose/throat (ENT) and cardiovascular involvement. GPA HE comprised 42 (13.00%) out of 323 GPA cases with reported blood eosinophil count. Both GPA subsets had a lower prevalence of respiratory, cardiovascular, and neurologic manifestations but more often renal and ocular involvement than EGPA. EGPA also had cutaneous and gastrointestinal signs more often than GPA with normal blood eosinophilia (GPA NE) but not GPA HE. The model differentiating EGPA from GPA HE, using ANCA status and clinical manifestations, had an AUC of 0.92, sensitivity of 96%, and specificity of 95%. Conclusion. Cardiovascular symptoms were more prevalent in the ANCA-negative subset than in the MPO-ANCA-positive one. Since EGPA and GPE HE share similarities in clinics, diagnostic misleading may result in an inappropriate therapeutic approach. Further studies are needed to optimize their differentiation and tailored therapy, including biologics.
immunology